Prof. Victoria P. Werth (University of Pennsylvania, USA) pointed out the need for new therapeutics in cutaneous lupus erythematosus (CLE) for patients resistant to conventional immunosuppressive agents .
Most therapeutic trials with novel agents focus on systemic lupus erythematosus (SLE) and exclude CLE patients. However, CLE and SLE share the same pathology. To solve this gap, a lupus community panel proposed to optimise future clinical trials . If skin improvement is strong enough when nested in an SLE study, treatment should be made available for patients with CLE irrespective of whether they meet SLE classification. A couple of biologics have shown activity in CLE, including the IL-12/IL-23 inhibitor ustekinumab. Ustekinumab was shown to result in significant improvement in disease activity, assessed in the responder index 4 in the SLE disease activity index 2000 (SLEDAI-2K) .
B cells: an important novel target
Please login to read the full text of the article.
If you have no account yet, please register now.
« Novel selective IL-23 blocker highly effective over 2 years Next Article
Treating keloids with lasers »